Clinical Evidence Supporting Pharmacogenomic Biomarker Testing Provided In US Food And Drug Administration Drug Labels: An Update

IMPORTANCE Genetic biomarkers that predict a drug’s efficacy or likelihood of toxicity are assuming increasingly important roles in the personalization of pharmacotherapy, but concern exists that evidence that links use of some biomarkers to clinical benefit is insufficient. Nevertheless, information about the use of biomarkers appears in the labels of many prescription drugs, whichmay add confusion to the clinical decision-making process.